Impel Pharmaceuticals Inc. Common Stock
IMPL
IMPL was delisted on the 15th of December, 2023.
36 hedge funds and large institutions have $141M invested in Impel Pharmaceuticals Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 16 reducing their positions, and 13 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
47% more capital invested
Capital invested by funds: $95.7M → $141M (+$44.9M)
0.11% more ownership
Funds ownership: 64.97% → 65.08% (+0.11%)
14% less funds holding
Funds holding: 42 → 36 (-6)
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
75% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.06M |
| 2 |
Millennium Management
New York
|
+$1.05M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$1M |
| 4 |
LCM
Laurion Capital Management
New York
|
+$912K |
| 5 |
LM
Lasry Marc
|
+$572K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.81M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.01M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$340K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$291K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$204K |
IMPL Hedge Fund Activity: Q2 2022 in Review
36 of the 5,960 institutional investors tracked by Wall St. Rank reported a position in Impel Pharmaceuticals Inc. Common Stock (IMPL) for Q2 2022, worth a combined $141M — up 47% from $95.7M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of IMPL and 8 opened new positions — a net loss of 5 holders — while 16 trimmed existing stakes and 4 added.
The largest buyer was Opaleye Management, opening a new position worth an estimated $1.06M. The largest seller was BlackRock, cutting an estimated $1.81M.
- 36 institutional investors held Impel Pharmaceuticals Inc. Common Stock (IMPL) as of Q2 2022, down from 42 in Q1 2022.
- Funds reported $141M of Impel Pharmaceuticals Inc. Common Stock stock for Q2 2022, up 47% quarter-over-quarter.
- 8 funds opened new Impel Pharmaceuticals Inc. Common Stock positions in Q2 2022 and 13 closed out, a net change of -5 holders.
- The largest Impel Pharmaceuticals Inc. Common Stock buyer in Q2 2022 was Opaleye Management, an estimated $1.06M added.
- The largest Impel Pharmaceuticals Inc. Common Stock seller in Q2 2022 was BlackRock, an estimated $1.81M sold.
Based on aggregated 13F filings for Q2 2022.